Neutralizing antibody seroprevalence in healthy Mexican adults against eight human and three simian adenovirus types, including those employed in COVID-19 Vaccines.

Autor: López, Raúl E., Alemán, Margarita Valdés, Cabrera Gaytán, David Alejandro, Santacruz Tinoco, Clara Esperanza, Alvarado Yaah, Julio Elias, Hernández, Yu Mei Anguiano, Miguel, Bernardo Martínez, Muñoz Medina, José Esteban, Gutiérrez, Nancy Sandoval, Lagunes, Ilse Ramos, Arroyo Pérez, José Antonio, Flores, Jesús Torres, González, Ramón A.
Předmět:
Zdroj: Veterinaria México OA; 2024 Special Issue, Vol. 11, p5-5, 1p
Abstrakt: Five of the eight vaccines approved in Mexico to be used against COVID-19 are adenovirus-based, including Gam-COVID-Vac (Sputnik V), Ad5-nCoV Covidecia, Ad26.COV2-S, and AZD1222 Covishield. AdV-based vaccines have shown promise due to their ability to induce robust B- and T-cell responses. However, studies indicate high levels of prior exposure to HAdV-C5 and neutralizing antibodies in the human population that could interfere with the efficacy of the vaccine, while the prevalence of antibodies against HAdV-D26 varies worldwide. In Mexico, data on AdV seroprevalence are scarce, hindering predictions about vaccine efficacy, immunity duration, and their use for boosters or seasonal application. In this work we have analyzed pre-COVID-19 pandemic and pre-COVID-19 vaccination blood samples from healthy Mexican adult donors for antibodies against different AdV types (from species A to F) and simian AdVs (SAdV-21, SAdV-25, and SAdV-31) using ELISA and neutralization assays. The highest levels of neutralizing antibodies were observed for HAdV-C5, HAdV-C6, HAdV-B14, and HAdV-F41, while SAdV-21, SAdV-25, and SAdV-31 showed negligible neutralization. HAdV-D36, HAdV-A12, and HAdV-E4 formed a separate cluster with intermediate neutralization levels. Notably, HAdV-D26 exhibited low neutralization, similar to developed countries. These findings show widespread and high prevalence of adenovirus in healthy individuals in Mexico, with levels that are similar to developing countries for HAdV-C5 or HAdV-F41, while more closely matching levels in developed countries for HAdV-D26. The data indicate that HAdV-D26 and SAdV21 are good vaccine vector candidates for the Mexican population due to their low prevalence. The data should contribute to plans for vaccine development and vaccination strategies by national health authorities, including seasonal vaccine application and the development of new AdV-based vaccines. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje